# Drug Development Feasibility Assessment
## TOP-TIER HYPOTHESES
### Hypothesis 3: HSP70 Enhancement (Revised Confidence: 0.58)
**MOST DEVELOPABLE** - Clear path forward with existing compounds
#### Druggability Assessment: HIGH ⭐⭐⭐⭐⭐
- **Multiple validated approaches**: Small molecule activators, gene therapy, pharmacological chaperones
- **Established PK/PD**: HSP70 induction is measurable and dose-dependent
- **CNS penetration**: Several HSP70 activators cross BBB effectively
#### Existing Chemical Matter & Clinical Pipeline:
**Immediate opportunities:**
- **Arimoclomol (ORY-2001)** - Orphazyme A/S
- Phase 2/3 complete for ALS (NCT03491462) - FAILED primary endpoint but showed biomarker effects
- Mechanism: HSP co-inducer, amplifies existing stress response
- **Available for licensing/repositioning**
- **17-AAG/Tanespimycin derivatives** - Multiple companies
- HSP90 inhibitors that indirectly boost HSP70
- CNS-penetrant analogs available (17-DMAG)
- **Established safety profile**
**Near-term candidates:**
- **Geranylgeranylacetone (GGA)** - Generic, Japan-approved
- Oral HSP70 inducer, excellent safety profile
- Currently in Phase 1 for ALS in Japan
- **Cost: <$50M to Phase 2**
#### Competitive Landscape:
- **Direct competitors**: Limited - most focus on protein clearance rather than disaggregation
- **Biogen/Ionis**: Antisense approaches (BIIB105/IONIS-MAPTRx for other proteinopathies)
- **Denali Therapeutics**: Transport vehicle technology could be synergistic
#### Safety Concerns - MODERATE:
- Chronic HSP induction can cause cellular stress
- Potential immune activation (HSPs are DAMPs)
- **Mitigation**: Pulsed dosing, biomarker monitoring
#### Development Timeline & Cost:
- **Phase 1**: 18-24 months, $15-25M (repurposing existing compounds)
- **Phase 2 POC**: 36 months, $75-100M
- **Total to Phase 2**: $90-125M, 4-5 years
- **Regulatory path**: 505(b)(2) for repositioned drugs, potential FDA breakthrough designation
---
### Hypothesis 1: PRMT Enhancement (Revised Confidence: 0.45)
**CHALLENGING BUT FEASIBLE** - Novel target class with emerging tools
#### Druggability Assessment: MODERATE ⭐⭐⭐
- **Enzyme target**: PRMT1/CARM1 are druggable methyltransferases
- **Challenge**: Most existing compounds are inhibitors, not activators
- **SAM/cofactor approach**: Could enhance activity through substrate availability
#### Existing Chemical Matter:
**Tool compounds available:**
- **PRMT1 inhibitors for reverse engineering**: MS023 (structural basis for activator design)
- **SAM analogs**: S-adenosyl-L-methionine derivatives for enhanced methylation
- **No direct PRMT activators in clinical development**
**Development approach:**
- **Allosteric activators**: Target regulatory sites rather than active site
- **Cofactor enhancement**: Increase SAM availability or PRMT1 expression
- **Antisense reduction of PRMT inhibitors**: Target endogenous negative regulators
#### Competitive Landscape:
- **Epigenetic space is crowded** but focused on inhibition
- **Constellation Pharmaceuticals** (acquired by MorphoSys): PRMT inhibitor expertise
- **Prelude Therapeutics**: EZH2/PRMT programs
- **No direct competitors for PRMT activation**
#### Safety Concerns - HIGH:
- **Global methylation changes**: Unpredictable off-target effects
- **Oncogenic risk**: Altered methylation linked to cancer
- **Developmental effects**: PRMTs essential for embryogenesis
#### Development Timeline & Cost:
- **Hit-to-lead**: 36-48 months, $40-60M (novel activator development)
- **IND-enabling**: 24 months, $25-35M
- **Phase 1**: 24 months, $20-30M
- **Total to Phase 2**: $85-125M, 6-8 years
- **High technical risk**: Novel mechanism, limited precedent
---
## SECOND-TIER HYPOTHESES
### Hypothesis 5: PARP1 Inhibition (Confidence: 0.35)
**IMMEDIATE REPURPOSING OPPORTUNITY** - Despite low confidence, established drugs available
#### Druggability Assessment: MAXIMUM ⭐⭐⭐⭐⭐
- **Multiple FDA-approved compounds**
- **Established CNS penetration data**
- **Well-characterized PK/PD**
#### Existing Compounds:
**FDA-approved PARPi's:**
- **Olaparib (Lynparza)** - AstraZeneca: Good CNS penetration
- **Niraparib (Zejula)** - GSK: Favorable BBB profile
- **Talazoparib (Talzenna)** - Pfizer: High brain/plasma ratio
**Clinical precedent:**
- Multiple oncology trials with CNS involvement
- **NCT04644068**: Olaparib for glioblastoma (CNS safety established)
#### Competitive Landscape:
- **Repligen/ADC Therapeutics**: PARP1-ADC programs
- **Limited ALS/neurodegeneration focus** - clear opportunity
#### Safety Concerns - WELL-CHARACTERIZED:
- **Hematologic toxicity**: Manageable with dose modifications
- **DNA repair impairment**: Requires biomarker monitoring
- **Drug interactions**: Extensive CYP inhibition data available
#### Development Timeline & Cost:
- **Phase 1**: 12-18 months, $8-15M (investigator-sponsored possible)
- **Phase 2**: 24-36 months, $40-60M
- **Total**: $50-75M, 3-4 years
- **Regulatory**: 505(b)(2) pathway, fast enrollment due to established compounds
---
### Hypothesis 4: G3BP1/2 Inhibition (Confidence: 0.45)
**TOOL COMPOUND AVAILABLE BUT EARLY STAGE**
#### Druggability Assessment: MODERATE ⭐⭐⭐
- **Protein-protein interaction target**: Challenging but precedented
- **RNA-binding domain**: Potentially druggable pockets identified
- **Limited chemical matter available**
#### Existing Chemical Matter:
**Research tools only:**
- **ISRIB analogs**: Affect stress granule formation indirectly
- **Academic collaborations needed**: No commercial programs identified
#### Development Timeline & Cost:
- **Hit-to-lead**: 48-60 months, $50-80M
- **High risk/high reward**: Novel target class
---
## THIRD-TIER HYPOTHESES (NOT RECOMMENDED)
### Hypotheses 2, 6, 7: Major Development Barriers
**Peptide delivery (H2)**: $200M+ to solve CNS delivery
**SR Kinase modulation (H6)**: Too many off-targets, complex biology
**TGM2 inhibition (H7)**: Weak rationale, essential target functions
---
## STRATEGIC RECOMMENDATIONS
### IMMEDIATE ACTIONS (0-6 months):
1. **IND-track PARP1 repurposing study** using olaparib
- Partner with academic ALS centers
- Biomarker-focused Phase 1b
- **Budget**: $5-8M
2. **HSP70 tool compound evaluation**
- License arimoclomol or GGA for ALS studies
- **Budget**: $2-5M licensing + $10M studies
### MEDIUM-TERM (1-3 years):
1. **PRMT activator discovery program**
- Academic partnerships for novel chemistry
- **Budget**: $15-25M over 2 years
### PORTFOLIO APPROACH:
- **60% resources**: HSP70 enhancement (highest probability)
- **25% resources**: PARP1 repurposing (fast/cheap)
- **15% resources**: PRMT1 activation (novel mechanism)
**Total 5-year investment**: $150-200M across three programs
**Peak funding**: Year 3-4 when multiple programs in clinical development
**Risk mitigation**: Diversified mechanisms with different technical/clinical risks